title: Metformin inhibits lung cancer cells proliferation through repressing microRNA-222.
abstract: Metformin, which is commonly used as an oral anti-hyperglycemic agent of the biguanide family, may reduce cancer risk and improve prognosis. However, the mechanism by which metformin affects various cancers, including lung cancer, remains unknown. MiR-222 induces cell growth and cell cycle progression via direct targeting of p27, p57 and PTEN in cancer cells. In the present study, we used A549 and NCI-H358 human lung cancer cell lines to study the effects and mechanisms of metformin. Metformin treatment reduced expression of miR-222 in these cells (p < 0.05). As a result, protein abundance of p27, p57 and PTEN were increased in cells exposed to metformin. Therefore, these data provide novel evidence for a mechanism that may contribute to the anti-neoplastic effects of metformin suggested by recent population studies and justifying further work to explore potential roles for it in lung cancer treatment.
authors: Department of Thoracic Surgery, General Hospital of the People's Liberation Army, Beijing, 100853, China, Wangyuqi301@sina.com.
authors: Yuqi
authors: Y
authors: Wang
authors: Weimin
authors: W
authors: Dai
authors: Xiangyang
authors: X
authors: Chu
authors: Bo
authors: B
authors: Yang
authors: Ming
authors: M
authors: Zhao
authors: Yu'e
authors: Y
authors: Sun
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism*; D008687:Metformin / Q000494:pharmacology*; D035683:MicroRNAs / Q000032:analysis / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs; D008687:Metformin; D055372:AMP-Activated Protein Kinases